Profile data is unavailable for this security.
About the company
Celcuity, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for treatment of multiple solid tumor indications. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients to benefit from targeted therapies. Its lead therapeutic candidate is gedatolisib, a potent, small molecule dual inhibitor that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Its mechanism of action and pharmacokinetic properties are highly differentiated from other investigational therapies that target PI3K or mTOR alone or together. Its initial clinical development program for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), HER2-negative, advanced or metastatic breast cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-56.51m
- Incorporated2017
- Employees45.00
- LocationCelcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
- Phone+1 (763) 392-0767
- Fax+1 (302) 655-5049
- Websitehttps://www.celcuity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AVITA Medical Inc | 50.14m | -35.38m | 424.16m | 207.00 | -- | 8.64 | -- | 8.46 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.40 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Shattuck Labs Inc | 1.66m | -87.30m | 426.32m | 75.00 | -- | 2.93 | -- | 257.29 | -2.05 | -2.05 | 0.0389 | 3.06 | 0.0091 | -- | -- | 22,093.33 | -47.85 | -29.14 | -53.15 | -32.42 | -- | -- | -5,268.44 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Theravance Biopharma Inc | 57.42m | -55.19m | 433.96m | 99.00 | -- | 2.03 | -- | 7.56 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Jasper Therapeutics Inc | 0.00 | -64.47m | 434.14m | 45.00 | -- | 4.10 | -- | -- | -6.19 | -6.19 | 0.00 | 7.03 | 0.00 | -- | -- | 0.00 | -90.00 | -- | -104.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Celcuity Inc | 0.00 | -56.51m | 439.53m | 45.00 | -- | 4.37 | -- | -- | -2.73 | -2.73 | 0.00 | 4.15 | 0.00 | -- | -- | 0.00 | -54.42 | -37.87 | -60.02 | -39.28 | -- | -- | -- | -- | -- | -- | 0.2821 | -- | -- | -- | -36.36 | -- | -7.92 | -- |
Invivyd Inc | 0.00 | -169.56m | 440.46m | 84.00 | -- | 1.78 | -- | -- | -1.55 | -1.55 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -48.47 | -- | -54.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.41 | -- | -- | -- |
Avid Bioservices Inc | 140.94m | -11.45m | 441.41m | 365.00 | -- | 2.40 | -- | 3.13 | -0.1816 | -0.1816 | 2.23 | 2.90 | 0.3144 | 3.18 | 5.49 | 386,131.50 | -2.55 | 10.73 | -3.11 | 14.01 | 12.52 | 22.72 | -8.12 | 25.92 | 0.8529 | -3.32 | 0.4502 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
Harrow Inc | 130.19m | -24.41m | 450.17m | 315.00 | -- | 6.33 | -- | 3.46 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
Alto Neuroscience Inc | 0.00 | -32.74m | 451.11m | 63.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | 1.41 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2133 | -- | -100.00 | -- | -201.62 | -- | -- | -- |
Aeon Biopharma Inc | 0.00 | -28.71m | 452.60m | 10.00 | -- | -- | 103.55 | -- | -0.7727 | -0.7727 | 0.00 | -3.28 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.5686 | -- | -- | -- | -- | 5.54 | -- | -- | -- |
OraSure Technologies, Inc. | 405.47m | 53.66m | 453.11m | 638.00 | 8.52 | 1.05 | 6.07 | 1.12 | 0.7204 | 0.7204 | 5.47 | 5.86 | 0.8748 | 3.15 | 7.31 | 635,536.10 | 11.58 | 0.7238 | 13.11 | 0.8212 | 44.25 | 46.94 | 13.23 | 1.13 | 8.57 | -- | 0.0018 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
PepGen Inc | 0.00 | -78.63m | 455.87m | 64.00 | -- | 3.10 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Inozyme Pharma Inc | 0.00 | -71.17m | 456.49m | 59.00 | -- | 3.25 | -- | -- | -1.39 | -1.39 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -41.86 | -45.00 | -45.82 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2417 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Ocugen Inc | 0.00 | -75.53m | 456.57m | 84.00 | -- | 7.82 | -- | -- | -0.3242 | -0.3242 | 0.00 | 0.2277 | 0.00 | -- | -- | 0.00 | -79.11 | -83.81 | -91.61 | -96.15 | -- | -- | -- | -446,793.90 | -- | -- | 0.0453 | -- | -- | -- | -39.38 | -- | 74.43 | -- |
Holder | Shares | % Held |
---|---|---|
Soleus Capital Management LP (Investment Management)as of 31 Dec 2023 | 2.18m | 9.01% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.12m | 8.75% |
Commodore Capital LPas of 31 Dec 2023 | 1.75m | 7.25% |
Perceptive Advisors LLCas of 31 Dec 2023 | 1.48m | 6.12% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 954.15k | 3.94% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 809.10k | 3.34% |
CapFinancial Partners LLCas of 31 Dec 2023 | 544.84k | 2.25% |
Baker Bros. Advisors LPas of 31 Dec 2023 | 535.48k | 2.21% |
Geode Capital Management LLCas of 31 Dec 2023 | 323.43k | 1.34% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 296.66k | 1.23% |